Kanghui Pharmaceutical (603139.SH) released its performance for the first half of the year, with a net loss attributable to the parent company of 40.2036 million yuan, an increase of 362.01%.

According to the report from Wise Wealth News APP, Kanghui Pharmaceutical (603139.SH) released its semi-annual report for 2025. The company's operating income was 248 million yuan, a decrease of 6.83% compared to the same period last year. The net loss attributable to shareholders of the listed company was 40.2036 million yuan, an increase of 362.01% year-on-year. The net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 42.8271 million yuan, an increase of 167.89% year-on-year. The basic loss per share was 0.4 yuan.